Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Biomaterials. 2019 Oct 18;227:119558. doi: 10.1016/j.biomaterials.2019.119558

Figure 4: Effect of combination treatment (TXT-NPs + DNmb) on tumor regression.

Figure 4:

Animals with tumor received 4 doses of TXT-NPs (12 mg/kg TXT dose-equivalent NPs) in combination with DNmb (3 mg/kg), both given simultaneous as an IV injection. The other groups were DNmb alone (3 mg/kg, as IV injection), TXT-Cremophor (12 mg/kg), and saline (n=3). Arrows indicate dosing schedule. Changes in a) bioluminance signal; p<0.05 (each group compared with saline group); b) body weight, p<0.05 for both DNmb and combination treatment when compared with saline control; TXT Cr-EL group shows no statistical significance with saline control; c) survival with time; and d) representative bioluminance images of untreated, TXT-NPs and the combination (DNmb+TXT-NPs) treated animals. Combination vs. other groups, p=0.01. Saline, vs. TXT Cr-EL or DNmb p=NS. Data are expressed as the mean ± s.e.m., n= 3 to 5. The combination treatment was most effective in terms of tumor regression, body weight gain, and survival as compared with other treatment groups. There was no tumor relapse in the combination group even after discontinuing the treatment, whereas DNmb alone treated group showed tumor relapse. Median survival for saline = 7 wks; DNmb =14 wks; TXT-Cr-EL = 9 wks; and DNmb + TXT-NP > 40 wks, which is beyond the study end point. Abbreviation, D is for days, whereas other time points are in weeks.